Newsletter

March 2019 Scorecard

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: January Scorecard Number of Signals 15 Percent Correct – Prev Close to 5-day Peak 100% Avg Increase – Next open to 5-day Peak 10% Other stats: Number of signals over $10/share 8 Number […]

0Comments

Lannett Receives FDA Approval for Aspirin and Extended-Release Dipyridamole Capsules

On March 27, Lannett Company, Inc. (LCI) reported that they have received FDA approval for their Abbreviated New Drug Application (ANDA) for Aspirin and Extended-Release Dipyridamole Capsules, 25mg/200mg. The drug is the therapeutic equivalent to Aggrenox Capsules, 25 mg/200 mg by Boehringer Ingelheim Pharmaceuticals. Total annual sales in the US for Aspirin and Extended-Release Dipyridamole […]

0Comments

February 2019 Scorecard

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: January Scorecard Number of Signals 11 Percent Correct – Prev Close to 5-day Peak 100% Avg Increase – Next open to 5-day Peak 6% Other stats: Number of signals over $10/share 9 Number […]

0Comments

Allakos Reports Positive Phase 1 Clinical Trial Results for AK002

On February 19, Allakos, Inc. (ALLK) announced positive Phase 1 clinical trial results for its drug AK002, which is used to treat eosinophil and mast cell related diseases. The drug is being tested on patients with indolent systemic mastocytosis (ISM), a debilitating disorder caused by the release of inflammatory mediators from mast cells, who had […]

0Comments

January 2019 Scorecard

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: January Scorecard Number of Signals 10 Percent Correct – Prev Close to 5-day Peak 90% Avg Increase – Next open to 5-day Peak 8% Other stats: Number of signals over $10/share 6 Number […]

0Comments

December 2018 Scorecard

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: December Scorecard Number of Signals 12 Percent Correct – Prev Close to 5-day Peak 75% Avg Increase – Next open to 5-day Peak 7% Other stats: Number of signals over $10/share 12 Number […]

0Comments

November 2018 Scorecard

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: November Scorecard Number of Signals 8 Percent Correct – Prev Close to 5-day Peak 88% Avg Increase – Next open to 5-day Peak 8% Other stats: Number of signals over $10/share 5 Number […]

0Comments

October 2018 Scorecard

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: October Scorecard Number of Signals 19 Percent Correct – Prev Close to 5-day Peak 100% Avg Increase – Next open to 5-day Peak 8% Other stats: Number of signals over $10/share 13 Number […]

0Comments

September 2018 Scorecard

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: August Scorecard Number of Signals 49 Percent Correct – Prev Close to 5-day Peak 92% Avg Increase – Next open to 5-day Peak 11% Other stats: Number of signals over $10/share 30 Number […]

0Comments

Paratek Receives FDA Approval of NUZYRA to Treat Bacterial Pneumonia and Skin Infections

On October 2, Paratek Pharmaceuticals, Inc. (PRTK) announced that the company received FDA approval of NUZYRA™ (omadacycline) to treat community-acquired bacterial pneumonia (CABP) and acute skin and skin structure infections (ABSSSI). NUZYRA is an antibiotic that can be administered either orally or through a once-daily IV treatment. Paratek plans to have the drug available in […]

0Comments